Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...
News Medical on MSN4d
Understanding how JAK inhibitors may increase blood clot risk
Why do medications that are supposed to help patients with chronic inflammatory diseases sometimes lead to blood clots?
Healio4d
VIDEO: Potential of mutant-specific therapeutics in myelofibrosis
In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.